Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

20151,573 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 16, Issue 2, pp. 141-151

Field-Weighted Citation Impact: 165.50